Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies
View/ Open
Author
Key, Timothy
Appleby, Paul
Travis, Ruth
Albanes, Demetrius
Alberg, Anthony
Barricarte, Aurelio
Black, Amanda
Boeing, Heiner
Bueno-de-Mesquita, H. Bas
Chan, June
Chen, Chu
Cook, Michael
Donovan, Jenny
Galan, Pilar
Gilbert, Rebecca
Giles, Graham
Giovannucci, Edward
Goodman, Gary
Goodman, Phyllis
Gunter, Marc
Hamdy, Freddie
Heliövaara, Markku
Helzlsouer, Kathy
Henderson, Brian
Hercberg, Serge
Hoffman-Bolton, Judy
Hoover, Robert
Johansson, Mattias
Khaw, Kay-Tee
King, Irena
Knekt, Paul
Kolonel, Laurence
Le Marchand, Loic
Männistö, Satu
Martin, Richard
Meyer, Haakon
Mondul, Alison
Moy, Kristin
Neal, David
Neuhouser, Marian
Palli, Domenico
Platz, Elizabeth
Pouchieu, Camille
Rissanen, Harri
Schenk, Jeannette
Severi, Gianluca
Tjønneland, Anne
Touvier, Mathilde
Trichopoulou, Antonia
Weinstein, Stephanie
Ziegler, Regina
Zhou, Cindy Ke
Allen, Naomi
Published Version
https://doi.org/10.3945/ajcn.115.114306Metadata
Show full item recordCitation
Key, Timothy J, Paul N Appleby, Ruth C Travis, Demetrius Albanes, Anthony J Alberg, Aurelio Barricarte, Amanda Black, et al. 2015. “Carotenoids, Retinol, Tocopherols, and Prostate Cancer Risk: Pooled Analysis of 15 Studies.” The American Journal of Clinical Nutrition 102 (5): 1142–57. https://doi.org/10.3945/ajcn.115.114306.Abstract
Background: Individual studies have suggested that circulating carotenoids, retinol, or tocopherols may be associated with prostate cancer risk, but the studies have not been large enough to provide precise estimates of associations, particularly by stage and grade of disease. Objective: The objective of this study was to conduct a pooled analysis of the associations of the concentrations of 7 carotenoids, retinol, alpha-tocopherol, and gamma-tocopherol with risk of prostate cancer and to describe whether any associations differ by stage or grade of the disease or other factors. Design: Principal investigators of prospective studies provided individual participant data for prostate cancer cases and controls. Risk by study-specific fifths of each biomarker was estimated by using multivariable-adjusted conditional logistic regression in matched case-control sets. Results: Data were available for up to 11,239 cases (including 1654 advanced stage and 1741 aggressive) and 18,541 controls from 15 studies. Lycopene was not associated with overall risk of prostate cancer, but there was statistically significant heterogeneity by stage of disease, and the OR for aggressive disease for the highest compared with the lowest fifth of lycopene was 0.65 (95% CI: 0.46, 0.91; P-trend = 0.032). No other carotenoid was significantly associated with overall risk of prostate cancer or with risk of advanced-stage or aggressive disease. For retinol, the OR for the highest compared with the lowest fifth was 1.13 (95% CI: 1.04, 1.22; P-trend = 0.015). For alpha-tocopherol, the OR for the highest compared with the lowest fifth was 0.86 (95% CI: 0.78, 0.94; P-trend < 0.001), with significant heterogeneity by stage of disease; the OR for aggressive prostate cancer was 0.74 (95% CI: 0.59, 0.92; P-trend = 0.001). gamma-Tocopherol was not associated with risk. Conclusions: Overall prostate cancer risk was positively associated with retinol and inversely associated with alpha-tocopherol, and risk of aggressive prostate cancer was inversely associated with lycopene and alpha-tocopherol. Whether these associations reflect causal relations is unclear.Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41292479
Collections
- SPH Scholarly Articles [6351]
Contact administrator regarding this item (to report mistakes or request changes)